article thumbnail

Eli Lilly agrees to provide free and lower-priced insulin in Minnesota to resolve 2018 lawsuit

Fierce Pharma

After reaching a settlement with Minnesota’s attorney general, Eli Lilly can close the book on a yearslong lawsuit in the state. | The company will provide its insulin products at $35 per month and donate free insulin at 15 clinics over the next five years. Meanwhile, Minnesota's claims against Novo Nordisk and Sanofi remain ongoing.

246
246
article thumbnail

WHO flags increasing resistance to GSK's HIV med Tivicay in some countries

Fierce Pharma

GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization since 2018 as a preferred treatment for the virus. |

Medicine 289
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Texas accuses Pfizer and contract manufacturer of providing ineffective ADHD drug to state's Medicaid program

Fierce Pharma

The lawsuit further accuses the companies of manipulating quality-control testing from 2012 to 2018 to ensure samples received passing grades. . | In its lawsuit, Texas says the companies knew that deficient manufacturing processes compromised the effectiveness of Quillivant XR.

article thumbnail

Novo Holdings, Gurnet Point team up to buy antibiotics maker Paratek for $462M

Fierce Pharma

Paratek's key selling point is its antibiotic, Nuzyra, which was expected to garner $500 million in peak sales at the time of its 2018 approval. Novo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million.

Biopharma 264
article thumbnail

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Back in 2018, Irish authorities hit Shire with a €398 million charge tied to that company’s rejection of AbbVie’s takeover bid in 2014. After years spent challenging a tax break fee tethered to its massive Shire buyout, Takeda has settled with Irish authorities. Takeda ultimately purchased Shire for $62 billion in 2019.

278
278
article thumbnail

After AstraZeneca mRNA deal, CanSino eyes other production partnerships: Reuters

Fierce Pharma

After jumping into the mRNA game back in 2018, CanSino has built a facility in Shanghai that can produce up to 200 million vaccine doses a year, the company’s co-founder and CEO Xuefeng Yu told Reuters in a recent interview.

article thumbnail

New FDA head needs to examine the accelerated approval program

World of DTC Marketing

The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said. Between 2011 and 2018, cumulative spending on 44 FDA-approved oral targeted therapy drugs was $3.5

FDA 234